Leqembi represents a significant milestone in our understanding of Alzheimer’s treatment. By targeting amyloid plaques—the protein structures that disrupt neural communication—this medication offers hope to millions of families wrestling with progressive memory loss. The drug’s ability to slow cognitive decline by over one-third suggests we’re moving beyond management toward meaningful intervention.
Neurological research continually challenges our understanding of brain health. Each breakthrough like Leqembi illuminates pathways for potentially preventing or dramatically reducing cognitive deterioration. For individuals and families facing Alzheimer’s, these advances aren’t abstract scientific achievements—they represent renewed possibility, preserved memories, and extended connections with loved ones. Understanding how we can protect and restore neural function remains one of the most compelling frontiers in medical science.
Eisai and Biogen’s Alzheimer’s drug Leqembi continued to slow progress of the disease with no new safety issues four years into treatment, according to new data presented at a medical meeting on Wednesday. An injectable version of the drug, currently given by intravenous…
